Doximity reaches about 80% of doctors, and Jim Jones says pharma advertising drives most of its revenue even though doctors use the tools for free.
Jim Jones says healthcare digital advertising is only about half as penetrated as the broader economy, while pharma's shift to digital grows the market 5% to 7% a year.
Jim Jones says Doximity could eventually charge health systems for its AI tools, with about $900m in net cash and 54% operating margins giving it room to do so.
Doximity's free doctor tools turn pharma ad budgets into cash
Doximity has turned free workflow tools into the main way pharma reaches prescribing doctors. Healthcare advertising is only about half as digital as the rest of the economy, and measurable returns keep pulling budgets across. With 90% gross margins, that growth converts to cash fast, which is why Jones values it on cash flows.
Takeaways
Doximity is a free doctor platform paid for by pharma. About 80% of doctors use it. Free tools include e-signing, secured messaging, telehealth calling, a CME-credit newsfeed and clinical reference. Pharma pays to reach prescribers, with one ad in every 11 news items. Hospital enterprise deals are minor.
Healthcare advertising has a long digital runway. Digital is about 75% penetrated across most of the economy but roughly half that in healthcare. The market grows 5% to 7% a year. Pharma spends about $10bn on consumer ads and $7bn on doctors, and a new 30-second risk-disclosure rule hurts TV.
Measurable returns pull pharma budgets toward Doximity. The Portal gives pharma real-time feedback on ad performance. Wallet share at big brands, those spending over $100m, moves from about 10% toward more than 50% over time, and advertiser value rises as doctor engagement rises.
Bundling beats best-in-class point tools. Rivals include pharma reps, banner ads, point solutions, telehealth providers and newsfeed providers. Jones says Doximity only needs tools that are good enough, because having everything in one place wins. Acquisitions, such as an AI clinical reference engine, raise engagement.
Margins turn growth into cash very quickly. Gross margins are about 90%, EBITDA margins 55% and operating margins 54%. Capex is about 1% of revenue. Net cash is around $900m, roughly $5 a share, funding buybacks and acquisitions.
AI is mainly a lever for new revenue. Jones says Doximity could eventually charge doctors, more likely through health systems, mainly for AI tools. Reustle argues agentic AI helps existing corporations more than it threatens them.
Value it on cash flows, not sales multiples. Jones says price-to-sales multiples were built for companies without earnings. Investors may treat Doximity as ad tech and withhold credit for growth duration, but he thinks the platform sustains the runway. High incremental margins can rapidly grow earnings power.
Risks Jones sees
The main risks are a competitor that takes doctors' attention, or a misstep that reduces doctor engagement on the platform.
Tariff talk and pressure on pharma profitability could lead pharma to cut advertising dollars.
Tap a name to go there · tap a line to see why they are linked